<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SUFENTANIL CITRATE- sufentanil citrateÂ injectionÂ </strong><br>Baxter Healthcare Corporation<br></p></div>
<h1>Sufentanil Citrate Injection, USP<br>CII</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="INV-ebc535f2-ec6c-4bc6-a047-a0f4b1bfabab"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><a name="INV-ced5f812-eb17-4192-8010-67c316bda29c"></a>Sufentanil Citrate Injection,
              USP is a sterile, nonpyrogenic, aqueous solution for intravenous and epidural
              injection. Each mL contains sufentanil citrate equivalent to 50 mcg (0.05 mg) of
              sufentanil in Water for Injection. pH 3.5â€“6.0; citric acid added, if needed, for pH
              adjustment. Contains no preservative. Sufentanil Citrate is a potent opioid analgesic
              chemically designated as
              N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide
              2-hydroxy-1,2,3-propanetricarboxylate (1:1) with the following structural formula:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53dbe21e-0b97-4271-a7af-2d18986adcd8&amp;name=Sufentanil-Figure-1.JPG"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="INV-b3a04a3c-8bc3-4f27-b653-7a75e318e99c"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section">
<a name="INV-cd5a8ca5-595d-4ead-9a5a-577500e1931a"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacology</h2>
<p class="First"><a name="INV-4726880f-32b7-4489-baf5-3e80b8888371"></a>Sufentanil is an opioid
                  analgesic. When used in balanced general anesthesia, sufentanil has been reported
                  to be as much as 10 times as potent as fentanyl. When administered intravenously
                  as a primary anesthetic agent with 100% oxygen, sufentanil is approximately 5 to 7
                  times as potent as fentanyl.</p>
<p><a name="INV-8e4b3bd6-e330-4bbc-9c71-f440b11d0def"></a>Assays of histamine in
                  patients administered sufentanil citrate have shown no elevation in plasma
                  histamine levels and no indication of histamine release.</p>
<p><a name="INV-befb6877-ce98-44ac-8d5d-69155eed9ffc"></a>(See dosage chart for more
                  complete information on the intravenous use of Sufentanil Citrate
                Injection.)</p>
</div>
<div class="Section">
<a name="INV-6fff89e6-2728-4607-a7a2-1c9650f8ce16"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacodynamics</h2>
<div class="Section">
<a name="INV-0d58112c-700e-4611-940e-6614bb28515c"></a><a name="section-3.2.1"></a><p></p>
<h3>Intravenous Use</h3>
<p class="First"><a name="INV-6972f782-f2e8-4e97-b37c-611cf827fbd0"></a>At intravenous doses up
                      to 8 mcg/kg, sufentanil is an analgesic component of general anesthesia; at
                      intravenous doses â‰¥ 8 mcg/kg, sufentanil produces a deep level of anesthesia.
                      Sufentanil produces a dose-related attenuation of catecholamine release,
                      particularly norepinephrine.</p>
<p><a name="INV-8c391d25-3be6-49b1-8945-bae825c5a145"></a>At intravenous dosagesâ‰¥ 8 mcg/kg, sufentanil produces hypnosis and anesthesia without the use of
                      additional anesthetic agents. A deep level of anesthesia is maintained at
                      these dosages, as demonstrated by EEG patterns. Dosages of up to 25 mcg/kg
                      attenuate the sympathetic response to surgical stress. The catecholamine
                      response, particularly norepinephrine, is further attenuated at doses of
                      sufentanil of 25-30 mcg/kg, with hemodynamic stability and preservation of
                      favorable myocardial oxygen balance.</p>
<p><a name="INV-38a06865-a75d-49fb-ab21-fb6d8683458c"></a>Sufentanil has an
                      immediate onset of action with relatively limited accumulation. Rapid
                      elimination from tissue storage sites allows for relatively more rapid
                      recovery as compared with equipotent dosages of fentanyl. At dosages of 1-2
                      mcg/kg, recovery times are comparable to those observed with fentanyl; at
                      dosages &gt; 2-6 mcg/kg, recovery times are comparable to enï¬‚urane,
                      isoï¬‚urane and fentanyl. Within the anesthetic dosage range of 8-30 mcg/kg of
                      sufentanil, recovery times are more rapid compared to equipotent fentanyl
                      dosages.</p>
<p><a name="INV-c4693d7c-edb5-4202-8d47-f5b8fa7f6fb5"></a>The vagolytic effects
                      of pancuronium may produce a dose-dependent elevation in heart rate during
                      sufentanil-oxygen anesthesia. Moderate doses of pancuronium or of a less
                      vagolytic neuromuscular blocking agent may be used to maintain a stable lower
                      heart rate and blood pressure during sufentanil-oxygen anesthesia. The
                      vagolytic effects of pancuronium may be reduced in patients administered
                      nitrous oxide with sufentanil.</p>
<p><a name="INV-6b072df6-08a6-4128-9517-5b96fc17ead1"></a>Preliminary data
                      suggest that in patients administered high doses of sufentanil, initial dosage
                      requirements for neuromuscular blocking agents are generally lower as compared
                      to patients given fentanyl or halothane, and comparable to patients given
                      enï¬‚urane.</p>
<p><a name="INV-499480ee-fef8-4e88-a0ff-70490673c7f6"></a><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> is
                      infrequently seen in patients administered sufentanil-oxygen anesthesia. The
                      use of nitrous oxide with high doses of sufentanil may decrease mean arterial
                      pressure, heart rate and <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>.</p>
<p><a name="INV-62d4b821-be58-4f9c-8b11-961b0cfacd1e"></a>Sufentanil at 20 mcg/kg
                      has been shown to provide more adequate reduction in intracranial volume than
                      equivalent doses of fentanyl, based upon requirements for furosemide and
                      anesthesia supplementation in one study of patients undergoing craniotomy.
                      During carotid endarterectomy, sufentanil-nitrous oxide/oxygen produced
                      reductions in cerebral blood ï¬‚ow comparable to those of enï¬‚urane-nitrous
                      oxide/oxygen. During cardiovascular surgery, sufentanil-oxygen produced EEG
                      patterns similar to fentanyl-oxygen; these EEG changes were judged to be
                      compatible with adequate general anesthesia.</p>
<p><a name="INV-8928b311-8ace-4181-bf23-fa99cd7cb02c"></a>The intraoperative use
                      of sufentanil at anesthetic dosages maintains <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, with a slight
                      reduction in systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> during the initial postoperative
                      period. The incidence of postoperative <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, need for vasoactive
                      agents and requirements for postoperative analgesics are generally reduced in
                      patients administered moderate or high doses of sufentanil as compared to
                      patients given inhalation agents.</p>
<p><a name="INV-8b50a3b4-c986-45bb-a935-67867a366d3f"></a>Skeletal muscle
                      <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> is related to the dose and speed of administration of sufentanil.
                      This muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> may occur unless preventative measures are taken (see<a href="#INV-9f5121e9-7c23-4a81-a36c-6d65925dd996">WARNINGS</a>).</p>
<p><a name="INV-0b3c46e7-54f4-471b-bcc8-7a9099bf8114"></a>Decreased respiratory
                      drive and increased airway resistance occur with sufentanil. The duration and
                      degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> are dose related when sufentanil is used at
                      sub-anesthetic dosages. At high doses, a pronounced decrease in pulmonary
                      exchange and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> may be produced.</p>
</div>
<div class="Section">
<a name="INV-e507be87-4b46-41f6-a317-921f70fb08e1"></a><a name="section-3.2.2"></a><p></p>
<h3>Epidural Use In Labor And
                    Delivery</h3>
<p class="First"><a name="INV-a21fcaf4-8722-477b-a4cc-4dcd4caf5fa2"></a>Onset of analgesic
                      effect occurs within approximately 10 minutes of administration of epidural
                      doses of sufentanil and bupivacaine. Duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> following a single
                      epidural injection of 10-15 mcg sufentanil and bupivacaine 0.125% averaged 1.7
                      hours.</p>
<p><a name="INV-e11d9020-f22d-4fd5-aceb-16a1ea23263e"></a>During labor and
                      vaginal delivery, the addition of 10-15 mcg sufentanil to 10 mL 0.125%
                      bupivacaine provides an increase in the duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> compared to
                      bupivacaine without an opioid. <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> from 15 mcg sufentanil plus 10 mL
                      0.125% bupivacaine is comparable to <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> from 10 mL of 0.25% bupivacaine
                      alone. Apgar scores of neonates following epidural administration of both
                      drugs to women in labor were comparable to neonates whose mothers received
                      bupivacaine without an opioid epidurally.</p>
</div>
</div>
<div class="Section">
<a name="INV-ec635878-54a0-42ad-b9a7-0d53901ffee1"></a><a name="section-3.3"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section">
<a name="INV-82e3cc8a-68fd-457a-865e-b04ce4b7e7a2"></a><a name="section-3.3.1"></a><p></p>
<h3>Intravenous Use</h3>
<p class="First"><a name="INV-44dc82ea-ae68-4760-91fd-6912ca58eaa2"></a>The pharmacokinetics of
                      intravenous sufentanil can be described as a three-compartment model with a                distribution time of 1.4 minutes, redistribution of 17.1 minutes and an
                      elimination half-life of 164 minutes in adults. The elimination half-life of
                      sufentanil is shorter (e.g. 97 Â± 42 minutes) in infants and children, and
                      longer in neonates (e.g. 434 Â± 160 minutes) compared to that of adolescents
                      and adults. The liver and small intestine are the major sites of
                      biotransformation. Approximately 80% of the administered dose is excreted
                      within 24 hours and only 2% of the dose is eliminated as unchanged drug.
                      Plasma protein binding of sufentanil, related to the alpha<span class="Sub">1</span> acid
                      glycoprotein concentration, was approximately 93% in healthy males, 91% in
                      mothers and 79% in neonates.</p>
</div>
<div class="Section">
<a name="INV-4cc37a43-4cc3-4df6-a878-b4b6349b9ff2"></a><a name="section-3.3.2"></a><p></p>
<h3>Epidural Use In Labor And
                    Delivery</h3>
<p class="First"><a name="INV-8c8bc199-a1c5-4f97-a98e-48be554be248"></a>After epidural
                      administration of incremental doses totaling 5-40 mcg sufentanil during labor
                      and delivery, maternal and neonatal sufentanil plasma concentrations were at
                      or near the 0.05-0.1 ng/mL limit of detection, and were slightly higher in
                      mothers than in their infants.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="INV-0fcc59d8-6a93-4e80-a08a-df187d8413e8"></a><a name="section-3.4"></a><p></p>
<h2>Clinical Studies</h2>
<div class="Section">
<a name="INV-8d629f18-d2e0-4937-961c-4949d02d36c6"></a><a name="section-3.4.1"></a><p></p>
<h3>Epidural Use In Labor And
                    Delivery</h3>
<p class="First"><a name="INV-0a3c6047-9ac3-43a4-a859-318eeb9e2814"></a>Epidural sufentanil was
                      tested in 340 patients in two (one single-center and one multi-center)
                      double-blind, parallel studies. Doses ranged from 10 to 15 mcg sufentanil and
                      were delivered in a 10 mL volume of 0.125% bupivacaine with and without
                      epinephrine 1:200,000. In all cases, sufentanil was administered following a
                      dose of local anesthetic to test proper catheter placement. Since epidural
                      opioids and local anesthetics potentiate each other, these results may not
                      reï¬‚ect the dose or efï¬?cacy of epidural sufentanil by itself.</p>
<p><a name="INV-311a1bfb-e5bc-4701-ae2a-ed42b53bb2f5"></a>Individual doses of
                      10-15 mcg sufentanil plus bupivacaine 0.125% with epinephrine provided
                      <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> during the ï¬?rst stage of labor with a duration of 1-2 hours. Onset
                      was rapid (within 10 minutes). Subsequent doses (equal dose) tended to have
                      shorter duration. <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> was profound (complete <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief) in 80% to 100%
                      of patients and a 25% incidence of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> was observed. The duration of
                      initial doses of sufentanil plus bupivacaine with epinephrine is approximately
                      95 minutes, and of subsequent doses, 70 minutes.</p>
<p><a name="INV-8ace26fe-eee3-4137-a0cb-7fd6daf906d0"></a>There are insufï¬?cient
                      data to critically evaluate neonatal neuromuscular and adaptive capacity
                      following recommended doses of maternally administered epidural sufentanil
                      with bupivacaine. However, if larger than recommended doses are used for
                      combined local and systemic <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, e.g., after administration of a single
                      dose of 50 mcg epidural sufentanil during delivery, then impaired neonatal
                      adaption to sound and light can be detected for 1 to 4 hours and if a dose of
                      80 mcg is used, impaired neuromuscular coordination can be detected for more
                      than 4 hours.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INV-be94b610-698e-4b69-bf4a-1b7ea42030ed"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><a name="INV-36e0716b-78c8-4d91-9711-4391991bde69"></a>Sufentanil Citrate Injection is
              indicated for intravenous administration in adults and pediatric patients:</p>
<p><a name="INV-dcdd62ea-c2d7-469e-84df-e63235fa92f9"></a>â€“ as an analgesic adjunct in
              the maintenance of balanced general anesthesia in patients who are intubated and
              ventilated. </p>
<p><a name="INV-112c03ec-e001-4736-a665-a27fccdcfe3f"></a>â€“ as a primary anesthetic agent
              for the induction and maintenance of anesthesia with 100% oxygen in patients
              undergoing major surgical procedures; in patients who are intubated and ventilated,
              such as cardiovascular surgery or neurosurgical procedures in the sitting position; to
              provide favorable myocardial and cerebral oxygen balance or when extended
              postoperative ventilation is anticipated.</p>
<p><a name="INV-cab63e73-8d00-43c1-af8e-dbe09113f999"></a>Sufentanil Citrate Injection is
              indicated for epidural administration as an analgesic combined with low dose
              bupivacaine, usually 12.5 mg per administration, during labor and vaginal delivery.</p>
<p><a name="INV-976ad317-c18c-4d0c-84ab-5cf85cd7ac68"></a>SEE <a href="#INV-7c0e42fa-d18f-46b6-85df-db59e76f7422">DOSAGE AND
              ADMINISTRATION</a> SECTION FOR MORE COMPLETE INFORMATION ON THE USE OF
              SUFENTANIL.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="INV-fd958e43-ad70-4a80-8abe-121ae79d1472"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a name="INV-04de4831-4dcb-4884-b0bb-91cf3daf7080"></a>Sufentanil Citrate Injection is
              contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or known
              intolerance to other opioid agonists.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="INV-26230fa2-c031-4e9a-a5a2-17bf383553bf"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><a name="INV-9f5121e9-7c23-4a81-a36c-6d65925dd996"></a>SUFENTANIL CITRATE INJECTION
              SHOULD BE ADMINISTERED ONLY BY PERSONS SPECIFICALLY TRAINED IN THE USE OF INTRAVENOUS
              AND EPIDURAL ANESTHETICS AND MANAGEMENT OF THE RESPIRATORY EFFECTS OF POTENT OPIOIDS.</p>
<p><a name="INV-5be8a4c7-ec0c-4a0b-8a5c-195d9ea112ec"></a>AN OPIOID ANTAGONIST,
              RESUSCITATIVE AND INTUBATION EQUIPMENT AND OXYGEN SHOULD BE READILY AVAILABLE.</p>
<p><a name="INV-f9f3f22e-1be9-49a1-a71d-e1a134d183a0"></a>PRIOR TO CATHETER INSERTION,
              THE PHYSICIAN SHOULD BE FAMILIAR WITH PATIENT CONDITIONS (SUCH AS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span> AT THE
              INJECTION SITE, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> DIATHESIS, ANTICOAGULANT THERAPY, ETC.) WHICH CALL FOR
              SPECIAL EVALUATION OF THE BENEFIT VERSUS RISK POTENTIAL.</p>
<div class="Section">
<a name="INV-9533cdbe-eade-45d2-98c6-c1d0af2ad8af"></a><a name="section-6.1"></a><p></p>
<h2>Intravenous Use</h2>
<p class="First"><a name="INV-d87f7849-8cbd-4d8d-8230-12b62b10ab5c"></a>Intravenous administration
                  or unintentional intravascular injection during epidural administration of
                  sufentanil citrate may cause skeletal <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, particularly of the truncal
                  muscles. The incidence and severity of <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> is dose related.
                  Administration of sufentanil may produce muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> with a more rapid onset
                  of action than that seen with fentanyl. Sufentanil may produce muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>
                  that involves the skeletal muscles of the neck and extremities. As with fentanyl,
                  muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> has been reported to occur or recur infrequently in the extended
                  postoperative period. The incidence of muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> associated with
                  intravenous sufentanil can be reduced by: <span class="Bold">1)</span>
                  administration of up to 1/4 of the full paralyzing dose of a non-depolarizing
                  neuromuscular blocking agent just prior to administration of sufentanil at dosages
                  up to 8 mcg/kg, <span class="Bold">2)</span> administration of a full
                  paralyzing dose of a neuromuscular blocking agent following <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>
                  when sufentanil is used in anesthetic dosages (above 8 mcg/kg) titrated by slow
                  intravenous infusion or <span class="Bold">3)</span> simultaneous
                  administration of sufentanil and a full paralyzing dose of a neuromuscular
                  blocking agent when sufentanil is used in rapidly administered anesthetic dosages
                  (above 8 mcg/kg).</p>
<p><a name="INV-6b224551-8e38-44b5-89e2-9a16dcf053d7"></a>The neuromuscular blocking
                  agents used should be compatible with the patientâ€™s cardiovascular status.
                  Adequate facilities should be available for postoperative monitoring and
                  ventilation of patients administered sufentanil. It is essential that these  facilities be fully equipped to handle all degrees of respiratory
                <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="INV-a75516de-3446-4db5-8b3a-22afa70a721a"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section">
<a name="INV-03fee57f-285d-4c78-a153-5f529e194a7d"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"><a name="INV-49ff861f-6a4f-4f85-a635-5e0274cb4dad"></a>The initial dose of
                  sufentanil should be appropriately reduced in elderly and debilitated patients.
                  The effect of the initial dose should be considered in determining supplemental
                  doses.</p>
<p><a name="INV-7bc5d5bc-4cc9-48b9-9a4a-fc1bb617a5fc"></a>Vital signs should be
                  monitored routinely.</p>
<p><a name="INV-deb1b33e-fe11-4781-8dab-6e9ecc87d876"></a>Nitrous oxide may produce
                  cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> when given with high doses of sufentanil (see <a href="#INV-4726880f-32b7-4489-baf5-3e80b8888371">CLINICAL
                  PHARMACOLOGY</a>).</p>
<p><a name="INV-5a971080-5285-4086-9fe5-97b4accbfadb"></a><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> has been
                  reported infrequently with sufentanil-oxygen anesthesia and has been responsive to
                  atropine. </p>
<p><a name="INV-9ca7f63b-991a-4e2c-bf6d-6a0b779c3abb"></a><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>
                  caused by opioid analgesics can be reversed by opioid antagonists such as
                  naloxone. Because the duration of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> produced by sufentanil
                  may last longer than the duration of the opioid antagonist action, appropriate
                  surveillance should be maintained. As with all potent opioids, profound <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>
                  is accompanied by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and diminished sensitivity to
                  CO<span class="Sub">2</span> stimulation which may persist into or recur in the postoperative
                  period. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> may be enhanced when sufentanil is administered in
                  combination with volatile inhalational agents and/or other central nervous system
                  depressants such as barbiturates, tranquilizers and other opioids. Appropriate
                  postoperative monitoring should be employed to ensure that adequate spontaneous
                  breathing is established and maintained prior to discharging the patient from the
                  recovery area. Respiration should be closely monitored following each
                  administration of an epidural injection of sufentanil.</p>
<p><a name="INV-5b101256-ad56-4db6-ba67-68de526db660"></a>Proper placement of the
                  needle or catheter in the epidural space should be veriï¬?ed before sufentanil is
                  injected to assure that unintentional intravascular or intrathecal administration
                  does not occur. Unintentional intravascular injection of sufentanil could result
                  in a potentially serious <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, including acute truncal muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> and
                  <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. Unintentional intrathecal injection of the full sufentanil/bupivacaine
                  epidural doses and volume could produce effects of high spinal anesthesia
                  including prolonged <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and delayed recovery. If <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is inadequate,
                  the placement and integrity of the catheter should be veriï¬?ed prior to the
                  administration of any additional epidural medications. Sufentanil should be
                  administered epidurally by slow injection.</p>
<div class="Section">
<a name="INV-5926a9a7-7c0f-4008-867b-dcf0e5dc8be8"></a><a name="section-7.1.1"></a><p></p>
<h3>Neuromuscular Blocking Agents</h3>
<p class="First"><a name="INV-d5d5bf86-ce37-486e-9162-52fd0245c8da"></a>The hemodynamic effects
                      and degree of skeletal <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> required should be considered in the
                      selection of a neuromuscular blocking agent. High doses of pancuronium may
                      produce increases in heart rate during sufentanil-oxygen anesthesia.
                      <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> have been reported with other muscle relaxants
                      during sufentanil-oxygen anesthesia; this effect may be more pronounced in the
                      presence of calcium channel and/or beta blockers. Muscle relaxants with no
                      clinically signiï¬?cant effect on heart rate (at recommended doses) would not
                      counteract the vagotonic effect of sufentanil; therefore, a lower heart rate
                      would be expected. Rare reports of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> associated with the concomitant
                      use of succinylcholine and sufentanil have been reported.</p>
</div>
<div class="Section">
<a name="INV-f71745db-337c-42af-8649-5022997f2d0c"></a><a name="section-7.1.2"></a><p></p>
<h3>Interaction With Calcium
                    Channel And Beta Blockers</h3>
<p class="First"><a name="INV-be2924fd-4298-43b4-b554-4dd4d385113c"></a>The incidence and
                      degree of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during induction with sufentanil may be
                      greater in patients on chronic calcium channel and beta blocker therapy. (See<a href="#INV-87f51db5-e22b-432e-be74-f91cabd2573e">Neuromuscular Blocking
                        Agents</a>.)</p>
</div>
<div class="Section">
<a name="INV-3c2ab7ff-a31f-4f0c-a9aa-3827781455c0"></a><a name="section-7.1.3"></a><p></p>
<h3>Interaction With Other
                    Central Nervous System Depressants</h3>
<p class="First"><a name="INV-c6f84760-d418-46e6-88e5-5e9a416395c4"></a>Both the magnitude and
                      duration of central nervous system and cardiovascular effects may be enhanced
                      when sufentanil is administered to patients receiving barbiturates,
                      tranquilizers, other opioids, general anesthetics or other CNS depressants. In
                      such cases of combined treatment, the dose of sufentanil and/or these agents
                      should be reduced.</p>
<p><a name="INV-cb961a4c-5afc-47ca-8458-86bc7aec0bf0"></a>The use of
                      benzodiazepines with sufentanil during induction may result in a decrease in
                      mean arterial pressure and systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>.</p>
</div>
<div class="Section">
<a name="INV-76080270-d32b-4c9e-b53b-db4dbe822d83"></a><a name="section-7.1.4"></a><p></p>
<h3>Head Injuries</h3>
<p class="First"><a name="INV-5640946f-da3d-4036-b344-89980b64bedb"></a>Sufentanil may obscure
                      the clinical course of patients with head injuries.</p>
</div>
<div class="Section">
<a name="INV-4746990c-02b1-4fe8-bc22-c3a25e25fe66"></a><a name="section-7.1.5"></a><p></p>
<h3>Impaired Respiration</h3>
<p class="First"><a name="INV-23389c33-85ca-4fef-ab6f-961455efd7fd"></a>Sufentanil should be
                      used with caution in patients with pulmonary disease, decreased respiratory
                      reserve or potentially compromised respiration. In such patients, opioids may
                      additionally decrease respiratory drive and increase airway resistance. During
                      anesthesia, this can be managed by assisted or controlled
                    respiration.</p>
</div>
<div class="Section">
<a name="INV-c50520c8-fa6f-479e-abdc-87c7ce4c2c4b"></a><a name="section-7.1.6"></a><p></p>
<h3>Impaired Hepatic Or Renal
                    Function</h3>
<p class="First"><a name="INV-bfc93004-4932-49e3-99cd-6e351ba7c173"></a>In patients with liver
                      or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">kidney dysfunction</span>, sufentanil citrate should be administered with caution
                      due to the importance of these organs in the metabolism and excretion of
                      sufentanil.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="INV-27d89da9-96c7-45f7-810d-18471dab07c3"></a><a name="section-7.1.7"></a><p></p>
<h3>Carcinogenesis, Mutagenesis,
                    Impairment Of Fertility</h3>
<p class="First"><a name="INV-e81821a0-c45a-4b4f-8c07-d19a67499733"></a>No long-term animal
                      studies of sufentanil have been performed to evaluate carcinogenic potential.
                      The micronucleus test in female rats revealed that single intravenous doses of
                      sufentanil as high as 80 mcg/kg (approximately 2.5 times the upper human
                      intravenous dose) produced no structural chromosome mutations. The Ames<span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> metabolic
                      activating test also revealed no mutagenic activity. See <a href="#INV-2b7b2991-580b-4141-a791-65b355d2b67e">Animal
                      Toxicology</a> for reproduction studies in rats and
                    rabbits.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="INV-f9b02cf0-d5e5-4410-94df-981bac9ad802"></a><a name="section-7.2"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="INV-bdbf0cb6-0fe6-4e3c-b07b-996f762d7fab"></a><a name="section-7.2.1"></a><p></p>
<h3>Teratogenic Effectsâ€”Pregnancy
                    Category C. </h3>
<p class="First"><a name="INV-192dd461-80d4-4b08-80df-14ac80346a7e"></a>Sufentanil has been
                      shown to have an embryocidal effect in rats and rabbits when given in doses
                      2.5 times the upper human intravenous dose for a period of 10 days to over 30
                      days. These effects were most probably due to maternal toxicity (decreased
                      food consumption with increased mortality) following prolonged administration
                      of the drug.</p>
<p><a name="INV-a7dc7f7c-ec1a-48a5-bc99-b7325bc3a20a"></a>No evidence of
                      teratogenic effects have been observed after administration of sufentanil
                      citrate in rats or rabbits.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="INV-b5d13757-dcff-4126-b875-9a96d1fa8dd6"></a><a name="section-7.3"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First"><a name="INV-17c0b2d7-796f-40cf-98ad-8f2905cd3239"></a>The use of epidurally
                  administered sufentanil in combination with bupivacaine 0.125% with or without
                  epinephrine is indicated for labor and delivery. (See <a href="#INV-36e0716b-78c8-4d91-9711-4391991bde69">INDICATIONS AND
                  USAGE</a> and <a href="#INV-7c0e42fa-d18f-46b6-85df-db59e76f7422">DOSAGE AND
                  ADMINISTRATION</a>.) Sufentanil is not recommended for intravenous use or
                  for use of larger epidural doses during labor and delivery because of potential
                  risks to the newborn infant after delivery. In clinical trials, one case of severe
                  <span class="product-label-link" type="condition" conceptid="314749" conceptname="Fetal bradycardia">fetal bradycardia</span> associated with maternal <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was reported within 8
                  minutes of maternal administration of sufentanil 15 mcg plus bupivacaine 0.125%
                  (10 mL total volume).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="INV-97668402-fd07-4c19-8734-a1ff3dbf7eb7"></a><a name="section-7.4"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"><a name="INV-002756b3-136c-4c66-a949-3cabedef76eb"></a>It is not known whether
                  sufentanil is excreted in human milk. Because fentanyl analogs are excreted in
                  human milk, caution should be exercised when sufentanil citrate is administered to
                  a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="INV-486bba52-d020-4c41-a977-be62e710fa70"></a><a name="section-7.5"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><a name="INV-a5c9633e-e290-4740-be65-7d9132804d9d"></a>The safety and efï¬?cacy of
                  intravenous sufentanil in pediatric patients as young as 1 day old undergoing
                  cardiovascular surgery have been documented in a limited number of cases. The
                  clearance of sufentanil in healthy neonates is approximately one-half that in
                  adults and children. The clearance rate of sufentanil can be further reduced by up
                  to a third in neonates with cardiovascular disease, resulting in an increase in
                  the elimination half-life of the drug.</p>
</div>
<div class="Section">
<a name="INV-19f0931b-1969-44ff-b8aa-89125bcb8505"></a><a name="section-7.6"></a><p></p>
<h2>Animal Toxicology</h2>
<p class="First"><a name="INV-2b7b2991-580b-4141-a791-65b355d2b67e"></a>The intravenous
                  LD<span class="Sub">50</span> of sufentanil is 16.8 to 18.0 mg/kg in mice, 11.8 to 13.0 mg/kg in
                  guinea pigs and 10.1 to 19.5 mg/kg in dogs. Reproduction studies performed in rats
                  and rabbits given doses up to 2.5 times the upper human intravenous dose for a
                  period of 10 to over 30 days revealed high maternal mortality rates due to
                  decreased food consumption and <span class="product-label-link" type="condition" conceptid="313601" conceptname="Oxygen supply absent">anoxia</span>, which preclude any meaningful
                  interpretation of the results. Epidural and intrathecal injections of sufentanil
                  in dogs and epidural injections in rats were not associated with
                <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="INV-81a58f69-f36d-4c30-8d6c-3ea8135670af"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><a name="INV-4efb2721-bcc3-4b0d-b6ba-11ff9e83fc38"></a>The most common adverse
              reactions of opioids are <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and skeletal <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>,
              particularly of the truncal muscles. Sufentanil may produce muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> that
              involves the skeletal muscles of the neck and extremities. See <a href="#INV-4726880f-32b7-4489-baf5-3e80b8888371">CLINICAL PHARMACOLOGY</a>,<a href="#INV-9f5121e9-7c23-4a81-a36c-6d65925dd996">WARNINGS</a> and <a href="#INV-49ff861f-6a4f-4f85-a635-5e0274cb4dad">PRECAUTIONS</a> on the
              management of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and skeletal <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>. <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>
              has been associated with the use of epidural opioids but was not reported in the
              clinical trials of epidurally administered sufentanil due to the use of indwelling
              catheters. The incidence of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> in patients without urinary catheters
              receiving epidural sufentanil is unknown; return of normal bladder activity may be
              delayed.</p>
<p><a name="INV-76a5a8ae-9533-4418-b785-0cb0bf5d5cdd"></a>The following adverse reaction
              information is derived from controlled clinical trials in 320 patients who received
              intravenous sufentanil during surgical anesthesia and in 340 patients who received
              epidural sufentanil plus bupivacaine 0.125% for <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> during labor. Based on the
              observed frequency, none of the reactions occurring with an incidence less than 1%
              were observed during clinical trials of epidural sufentanil used during labor and
              delivery (N=340).</p>
<p><a name="INV-804877cd-1ff0-4fd4-acad-3963766a6c40"></a>In general, cardiovascular and
              musculoskeletal adverse experiences were not observed in clinical trials of epidural
              sufentanil. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> was observed 7 times more frequently in intravenous trials
              than in epidural trials. The incidence of central nervous system, dermatological and
              gastrointestinal adverse experiences was approximately 4 to 25 times higher in studies
              of epidural use in labor and delivery.</p>
<p><a name="INV-3982158a-ab42-4239-80fe-57641932f6ee"></a><span class="Bold">Probably Causally Related: Incidence greater than 1% â€“
                Derived from clinical trials</span></p>
<p><a name="INV-745da5c4-081d-445b-8824-e3216f2db1f8"></a>(See preceding paragraph)</p>
<p><a name="INV-bb98d0e3-3097-4147-bd66-09ced5804046"></a>Cardiovascular â€“ <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>*,
              <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>*, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>*</p>
<p><a name="INV-17e1eaa1-0c0e-4195-8ddb-39cf55000c37"></a>Musculoskeletal â€“ chest wall
              <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>*</p>
<p><a name="INV-b9af1aa2-9b95-4de5-a003-509068114bee"></a>Central Nervous System â€“
              <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>* </p>
<p><a name="INV-469d1a75-c470-4b14-bc99-b07e125852d7"></a>Dermatological â€“ <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (25%)</p>
<p><a name="INV-cf1e0462-a908-444e-b1c7-e55dc67a00f2"></a>Gastrointestinal â€“ <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>*,
              <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>*</p>
<p><a name="INV-3821b4ba-5dbd-4f9c-ae9e-a9f1e54ec3a6"></a>*Incidence 3% to 9%</p>
<p><a name="INV-1127edc3-ade7-44fd-93ef-868991328e99"></a><span class="Bold">Probably Causally Related: Incidence less than 1% â€“ Derived
                from clinical trials</span></p>
<p><a name="INV-8104f3e1-28ec-4d53-bd25-fb6227cf0f5b"></a>(Adverse events reported in
              post-marketing surveillance, not seen in clinical trials, are <span class="Italics">italicized</span>)</p>
<p><a name="INV-831c1438-a573-4820-a9c7-a6330c41b08c"></a><span class="Italics">Body as a whole â€“ <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span></span></p>
<p><a name="INV-d74573bb-7838-457b-9118-66b171886bcf"></a>Cardiovascular â€“ <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>*,
              <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>*, <span class="Italics"><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span></span></p>
<p><a name="INV-5c0fb36f-11d5-4617-a08a-c388eb36d8c4"></a>Central Nervous System â€“
              <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>*</p>
<p><a name="INV-f18bfdfb-b5fd-4a21-a0be-d9196b3e49ab"></a>Dermatological â€“ <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>*</p>
<p><a name="INV-bae03184-3b3d-45e4-bc03-a0e81f803c80"></a><span class="Italics">Musculoskeletal â€“ skeletal <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> of neck and  extremities</span></p>
<p><a name="INV-58402494-a0f9-4dc1-8e84-51a839eb9b55"></a>Respiratory â€“ <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>*,
              <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>*, postoperative <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>*</p>
<p><a name="INV-8c89e4aa-caec-4a0a-89fe-13a986523155"></a>Miscellaneous â€“ intraoperative
              muscle movement*</p>
<p><a name="INV-4e60007e-f518-4a5f-981b-b1e6681e2bf6"></a>*Incidence 0.3 to
            1%</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="INV-8dc80055-94be-4cd3-a266-1c8d6e504f25"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First"><a name="INV-895d0508-5ea2-469d-b67d-547f08d9f9bc"></a>Sufentanil Citrate Injection is
              a Schedule II controlled drug substance that can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the
              morphine type and therefore has the potential for being abused.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="INV-c71df83e-62a8-4312-a435-2fb1e8fc59ab"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><a name="INV-f4892b68-37e2-4e19-961b-48413f7532c1"></a>Overdosage is manifested by an
              extension of the pharmacological actions of sufentanil (see <a href="#INV-4726880f-32b7-4489-baf5-3e80b8888371">CLINICAL PHARMACOLOGY</a>)
              as with other potent opioid analgesics. The most serious and significant effect of
              <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> for both intravenous and epidural administration of sufentanil is respiratory
              <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Intravenous administration of an opioid antagonist such as naloxone should
              be employed as a speciï¬?c antidote to manage <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. The duration of
              <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> following overdosage with sufentanil may be longer than the
              duration of action of the opioid antagonist. Administration of an opioid antagonist
              should not preclude more immediate countermeasures. In the event of overdosage, oxygen
              should be administered and ventilation assisted or controlled as indicated for
              <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span> or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. A patent airway must be maintained, and a nasopharyngeal
              airway or endotracheal tube may be indicated. If depressed respiration is associated
              with muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, a neuromuscular blocking agent may be required to facilitate
              assisted or controlled respiration. Intravenous ï¬‚uids and vasopressors for the
              treatment of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and other supportive measures may be employed.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="INV-74dfc318-ff96-4ca8-9068-4da13f0d646b"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><a name="INV-7c0e42fa-d18f-46b6-85df-db59e76f7422"></a>The dosage of sufentanil should
              be individualized in each case according to body weight, physical status, underlying
              pathological condition, use of other drugs, and type of surgical procedure and
              anesthesia. In obese patients (more than 20% above ideal total body weight), the
              dosage of sufentanil should be determined on the basis of lean body weight. Dosage
              should be reduced in elderly and debilitated patients (see <a href="#INV-49ff861f-6a4f-4f85-a635-5e0274cb4dad">PRECAUTIONS</a>).</p>
<p><a name="INV-7fb24d6f-8a34-49fa-80b4-1e2e84e4704e"></a>Vital signs should be monitored
              routinely.</p>
<p><a name="INV-4e10724f-b8cb-4e7f-b899-c6db11877ff6"></a>Because the clearance of
              sufentanil is reduced in neonates, especially those with cardiovascular disease, the
              dose of sufentanil should be reduced accordingly (see <a href="#INV-49ff861f-6a4f-4f85-a635-5e0274cb4dad">PRECAUTIONS</a>).</p>
<div class="Section">
<a name="INV-b583b62c-a8b5-4be6-9f95-25ac03a9aa53"></a><a name="section-11.1"></a><p></p>
<h2>Intravenous Use</h2>
<p class="First"><a name="INV-1c4e30e4-2687-41a2-b858-72da84f36465"></a>Sufentanil citrate may be
                  administered intravenously by slow injection or infusion <span class="Bold">1)</span> in doses up to 8 mcg/kg as an analgesic adjunct to general
                  anesthesia and <span class="Bold">2)</span> in doses â‰¥ 8 mcg/kg as a
                  primary anesthetic agent for induction and maintenance of anesthesia (see<a href="#INV-87f51db5-e22b-432e-be74-f91cabd2573e">Dosage Range Chart</a>).
                  If benzodiazepines, barbiturates, inhalation agents, other opioids or other
                  central nervous system depressants are used concomitantly, the dose of sufentanil
                  and/or these agents should be reduced (see <a href="#INV-49ff861f-6a4f-4f85-a635-5e0274cb4dad">PRECAUTIONS</a>). In all
                  cases, dosage should be titrated to individual patient response.</p>
<div class="Section">
<a name="INV-ca3ca1cd-7549-4740-8700-c7f720d44944"></a><a name="section-11.1.1"></a><p></p>
<h3>Usage In Children</h3>
<p class="First"><a name="INV-c65eb622-776f-4c9d-9526-a6d52565026c"></a>For induction and
                      maintenance of anesthesia in pediatric patients less than 12 years of age
                      undergoing cardiovascular surgery, an anesthetic dose of 10-25 mcg/kg
                      administered with 100% oxygen is generally recommended. Supplemental dosages
                      of up to 25-50 mcg are recommended for maintenance, based on response to
                      initial dose and as determined by changes in vital signs indicating surgical
                      stress or lightening of anesthesia.</p>
</div>
<div class="Section">
<a name="INV-5892721e-58e4-4ec5-91f4-93b530d9a03f"></a><a name="section-11.1.2"></a><p></p>
<h3>Premedication</h3>
<p class="First"><a name="INV-3ea6cdae-a4e7-44d5-96fc-989577093cfe"></a>The selection of
                      preanesthetic medications should be based upon the needs of the individual
                      patient.</p>
</div>
<div class="Section">
<a name="INV-228bed33-533e-4745-ab8f-21e9bd6e96bd"></a><a name="section-11.1.3"></a><p></p>
<h3>Neuromuscular Blocking Agents</h3>
<p class="First"><a name="INV-87f51db5-e22b-432e-be74-f91cabd2573e"></a>The neuromuscular
                      blocking agent selected should be compatible with the patientâ€™s condition,
                      taking into account the hemodynamic effects of a particular muscle relaxant
                      and the degree of skeletal <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> required (see <a href="#INV-4726880f-32b7-4489-baf5-3e80b8888371">CLINICAL
                      PHARMACOLOGY</a>, <a href="#INV-9f5121e9-7c23-4a81-a36c-6d65925dd996">WARNINGS</a> and<a href="#INV-49ff861f-6a4f-4f85-a635-5e0274cb4dad">PRECAUTIONS</a>).</p>
<table frame="void" width="600">
<col align="left" width="300">
<col align="left" width="300*">
<thead valign="bottom"><tr class="Last" valign="bottom"><td align="center" colspan="2" valign="top"><span class="Bold">ADULT DOSAGE RANGE CHART for Intravenous use
                              (expressed as sufentanil)</span></td></tr></thead>
<tbody valign="top">
<tr valign="top"><td align="center" colspan="2" valign="top"><span class="Bold">ANALGESIC COMPONENT TO GENERAL ANESTHESIA
                              TOTAL DOSAGE REQUIREMENTS OF 1 MCG/KG/HR OR LESS ARE
                            RECOMMENDED</span></td></tr>
<tr valign="top">
<td align="center" valign="top"><span class="Bold">TOTAL DOSAGE</span></td>
<td align="center" valign="top"><span class="Bold">MAINTENANCE DOSAGE</span></td>
</tr>
<tr valign="top"><td align="center" colspan="2" valign="top"><span class="Bold">ANALGESIC DOSAGES</span></td></tr>
<tr valign="top">
<td align="left" valign="top">
<span class="Bold">Incremental or
                              Infusion</span><br>1â€“2 mcg/kg (expected duration of anesthesia 1â€“2 hours).
                            Approximately 75% or more of the total sufentanil dosage may be
                            administered prior to intubation by either slow injection or infusion
                            titrated to individual patient response. Dosages in this range are generally administered with nitrous oxide/oxygen in patients undergoing                            general surgery in which endotracheal intubation and mechanical
                            ventilation are required.</td>
<td align="left" valign="top">
<span class="Bold">Incremental</span><br>10â€“25 mcg (0.2â€“0.5 mL) may be administered in increments as needed
                            when movement and/or changes in vital signs indicate surgical stress or
                            lightening of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Supplemental dosages should be individualized
                            and adjusted to the remaining operative time anticipated. <br><span class="Bold">Infusion</span><br>
                            Sufentanil citrate may be administered as an intermittent or continuous
                            infusion as needed in response to signs of lightening of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. In
                            absence of signs of lightening of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, infusion rates should
                            always be adjusted downward until there is some response to surgical
                            stimulation. Maintenance infusion rates should be adjusted based upon
                            the induction dose of sufentanil so that the total dose does not exceed
                            1 mcg/kg/hr of expected surgical time. Dosage should be individualized
                            and adjusted to the remaining operative time anticipated.</td>
</tr>
<tr valign="top">
<td align="left" valign="middle"></td>
<td align="left" valign="middle"></td>
</tr>
<tr class="Last" valign="top">
<td align="left" valign="middle"></td>
<td align="left" valign="middle"></td>
</tr>
</tbody>
</table>
<table border="1" frame="border" width="600">
<col align="left" width="300*">
<col align="left" width="300*">
<tbody class="Headless" valign="top">
<tr class="First" valign="top"><td align="center" colspan="2" valign="top"><span class="Bold">ANALGESIC DOSAGES</span></td></tr>
<tr class="Last" valign="top">
<td align="left" valign="top">
<span class="Bold">Incremental or
                              Infusion</span><br>2-8Â mcg/kg (expected duration of anesthesia 2â€“8Â hours).
                            Approximately 75% or less of the total calculated sufentanil dosage may
                            be administered by slow injection or infusion prior to intubation,
                            titrated to individual patient response. Dosages in this range are
                            generally administered with nitrous oxide/oxygen in patients undergoing
                            more complicated major surgical procedures in which endotracheal
                            intubation and mechanical ventilation are required. At dosages in this
                            range, sufentanil has been shown to provide some attenuation of
                            sympathetic reflex activity in response to surgical stimuli, provide
                            hemodynamic stability and provide relatively rapid recovery.</td>
<td align="left" valign="top">
<span class="Bold">Incremental</span><br>10â€“50Â mcg (0.2â€“1Â mL) may be administered in increments as needed
                            when movement and/or changes in vital signs indicate surgical stress or
                            lightening of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Supplemental dosages should be individualized
                            and adjusted to the remaining operative time anticipated. Â <br><span class="Bold">Infusion</span><br>Sufentanil citrate may be administered as an intermittent or
                            continuous infusion as needed in response to signs of lightening of
                            <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. In absence of signs of lightening of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, infusion
                            rates should always be adjusted downward until there is some response to
                            surgical stimulation. Maintenance infusion rates should be adjusted
                            based upon the induction dose of sufentanil so that the total dose does
                            not exceed 1Â mcg/kg/hr of expected surgical time. Dosage should be
                            individualized and adjusted to the remaining operative time
                          anticipated.</td>
</tr>
</tbody>
</table>
<table border="1" frame="border" width="600">
<col align="left" width="300*">
<col align="left" width="300*">
<tbody class="Headless" valign="top">
<tr class="First" valign="top"><td align="center" colspan="2" valign="top"><span class="Bold">ANESTHETIC DOSAGES</span></td></tr>
<tr class="Last" valign="top">
<td align="left" valign="middle">
<span class="Bold">Incremental or
                              Infusion</span><br>8â€“30Â mcg/kg (anesthetic doses). At this anesthetic dosage range,
                            sufentanil is generally administered as a slow injection, as an infusion
                            or as an injection followed by an infusion. Sufentanil with 100% oxygen
                            and a muscle relaxant has been found to produce sleep at dosages â‰¥
                            8Â mcg/kg and to maintain a deep level of anesthesia without the use of
                            additional anesthetic agents. The addition of N2O to these dosages will
                            reduce systolic blood pressure. At dosages in this range of up to
                            25Â mcg/kg, catecholamine release is attenuated. Dosages of 25â€“30Â mcg/kg
                            have been shown to block sympathetic response including catecholamine
                            release. High doses are indicated in patients undergoing major surgical
                            procedures in which endotracheal intubation and mechanical ventilation
                            are required, such as cardiovascular surgery and neurosurgery in the
                            sitting position with maintenance of favorable myocardial and cerebral
                            oxygen balance. Postoperative observation is essential and postoperative
                            mechanical ventilation may be required at the higher dosage range due to
                            extended postoperative <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Dosage should be titrated
                            to individual patient response.</td>
<td align="left" valign="top">
<span class="Bold">Incremental</span><br>Depending on the initial dose, maintenance doses of 0.5â€“10Â mcg/kg
                            may be administered by slow injection in anticipation of surgical stress
                            such as incision, sternotomy or cardiopulmonary bypass. <span class="Bold"><br>Infusion</span><br>Sufentanil citrate may be administered by continuous or
                            intermittent infusion as needed in response to signs of lightening of
                            anesthesia. In the absence of lightening of anesthesia, infusion rates
                            should always be adjusted downward until there is some response to
                            surgical stimulation. The maintenance infusion rate for sufentanil
                            should be based upon the induction dose so that the total dose for the
                            procedure does not exceed 30Â mcg/kg.</td>
</tr>
</tbody>
</table>
<p><a name="INV-ad50b37a-3c96-4ff9-b6c3-8850744fd789"></a>In patients
                      administered high doses of sufentanil, it is essential that qualiï¬?ed personnel
                      and adequate facilities are available for the management of postoperative
                      <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p><a name="INV-d73647fd-b59f-4138-b178-c6666dcb89a9"></a>Also see <a href="#INV-9f5121e9-7c23-4a81-a36c-6d65925dd996">WARNINGS</a> and<a href="#INV-49ff861f-6a4f-4f85-a635-5e0274cb4dad">PRECAUTIONS</a>
                      sections.</p>
<p><a name="INV-ecadf9bb-ce1f-456f-8369-00269735ab0c"></a>For purposes of
                      administering small volumes of Sufentanil Citrate Injection accurately, the
                      use of a tuberculin syringe or equivalent is recommended.</p>
<table frame="void" width="600">
<col align="left" width="600*">
<thead valign="bottom"><tr class="Last" valign="bottom"><td align="center" valign="top">EPIDURAL USE IN LABOR AND DELIVERY</td></tr></thead>
<tbody valign="top">
<tr valign="top"><td class="Toprule" align="left" valign="top">Proper placement of the
                            needle or catheter in the epidural space should be veriï¬?ed before
                            sufentanil citrate is injected to assure that unintentional
                            intravascular or intrathecal administration does not occur.
                            Unintentional intravascular injection of sufentanil could result in a
                            potentially serious <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, including acute truncal muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>
                            and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. Unintentional intrathecal injection of the full
                            sufentanil-bupivacaine epidural doses and volume could produce effects
                            of high spinal anesthesia, including prolonged <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and delayed
                            recovery. If <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is inadequate, the placement and integrity of the
                            catheter should be veriï¬?ed prior to the administration of any additional
                            epidural medications. Sufentanil should be administered by slow
                            injection. Respiration should be closely monitored following each
                            administration of an epidural injection of sufentanil.</td></tr>
<tr class="Last" valign="top"><td align="left" valign="top">
<span class="Bold">DOSAGE FOR LABOR
                              AND DELIVERY</span><br>The recommended dosage is sufentanil 10â€“15 mcg administered with 10
                            mL bupivacaine 0.125% with or without epinephrine. Sufentanil and
                            bupivacaine should be mixed together before administration. Doses can be
                            repeated twice (for a total of three doses) at not less than one hour
                            intervals until delivery.</td></tr>
</tbody>
</table>
<p><a name="INV-833f5f79-b619-4657-a05d-2239fa5b5f7c"></a><span class="Bold">Parenteral drug products should be inspected
                        visually for particulate matter and discoloration prior to administration,
                        whenever solution and container permit.</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="INV-6d7219b6-e0e7-4f33-9b5e-b7254efed786"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><a name="INV-c0972d09-e693-4ee8-a38a-271d3000fff9"></a>Sufentanil Citrate Injection,
              USP, equivalent to 50 mcg (0.05 mg) sufentanil per mL, is available in the following:</p>
<p><a name="INV-e9c8f8f9-3317-4bc2-9a0e-01d179b81831"></a>1 mL (50 mcg) DOSETTE ampuls
              packaged in 10s (NDC 10019-050-43)</p>
<p><a name="INV-6a52ca5d-33ce-42e0-89a7-59a23145ade3"></a>2 mL (100 mcg) DOSETTE ampuls
              packaged in 10s (NDC 10019-050-21)</p>
<p><a name="INV-92baff8c-7a55-4b12-8063-c076095e05af"></a>5 mL (250 mcg) DOSETTE ampuls
              packaged in 10s (NDC 10019-050-06)</p>
<div class="Section">
<a name="INV-a6e01590-01af-45f8-b2db-67e50d5eb926"></a><a name="section-12.1"></a><p></p>
<h2>Storage</h2>
<p class="First"><a name="INV-17459395-a83a-459b-85b6-f499f1933238"></a><span class="Bold">PROTECT FROM LIGHT: Keep covered in carton until time of
                    use.</span></p>
<p><a name="INV-05480c43-d07d-408e-b2a9-792c832527ad"></a><span class="Bold">Store at 20Ëš-25ËšC (68Ëš-77ËšF), excursions permitted to
                    15Ëš-30ËšC (59Ëš-86ËšF) [see USP Controlled Room Temperature].</span></p>
<p><a name="INV-c98debe8-6e3d-438f-9f1d-218c2c791f8d"></a>Baxter and Dosette are
                  trademarks of Baxter International Inc., or its subsidiaries.</p>
<p><a name="INV-6b277ecd-669c-4b64-9e45-02fe50ceb9a8"></a>Manufactured by</p>
<p><a name="INV-9509ec7b-3ea7-4e50-8df4-217d706b450a"></a><span class="Bold">Baxter Healthcare Corporation</span></p>
<p><a name="INV-d7552a59-3584-4db0-975f-d977c61880e4"></a>Deerfield, IL 60015 USA</p>
<p><a name="INV-f8a8e018-77a1-46ee-b6be-fda280ab3d1a"></a>For Product Inquiry 1 800
                  ANA DRUG (1-800-262-3784)</p>
<p><a name="INV-33b26b3b-06ba-43a3-a0ab-5cd9b11a3bd8"></a>MLT-7/1.0</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SUFENTANIL CITRATEÂ 		
					</strong><br><span class="contentTableReg">sufentanil citrate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10019-050</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, EPIDURAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>sufentanil citrate</strong> (sufentanil) </td>
<td class="formItem"></td>
<td class="formItem">0.05Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-050-43</td>
<td class="formItem">10  in 1.0 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:10019-050-21</td>
<td class="formItem">10  in 1.0 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:10019-050-06</td>
<td class="formItem">10  in 1.0 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Baxter Healthcare Corporation</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>CBFF0147-491D-36E5-8450-17D96126BDC8</div>
<div>Set id: 53dbe21e-0b97-4271-a7af-2d18986adcd8</div>
<div>Version: 1</div>
<div>Effective Time: 20060227</div>
</div>
</div>Â <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
